Security key
74019P207
PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (DTIL)
CUSIP: 74019P207
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.000005 par value per share
- Total 13F shares
- 4,649,562
- Total 13F value
- $25,664,758
- Share change
- +211,624
- SEC-reported price per share
- $5.52
- Number of holders
- 54
- Value change
- +$1,234,800
- Number of buys
- 25
- Number of sells
- 17
- Shares outstanding
- 25,804,443
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
54
Top holders
10
DTIL full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
PRECISION BIOSCIENCES INC SEC filings
PRECISION BIOSCIENCES INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74019P207
Recent filing periods:
Ownership snapshot
Top reported holders of DTIL - PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Readout Capital, LP
Disclosed value leader
Readout Capital, LP
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
3/4/5
13F
Lead comparable stake: 9.4%
13D/G row: Readout Capital, LP
Showing 1-6 of 15 holder rows.
Quick read
Readout Capital, LP leads the comparable SEC ownership view at 9.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Readout Capital, LP's linked filing trail.
Comparable ownership
Top 5
Readout Capital, LP
9.4%
Weinstein Benjamin
5.2%
NOVARTIS PHARMA AG
3.7%
HIGHBRIDGE CAPITAL MANAGEMENT LLC
3.7%
Bleichroeder LP
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Readout Capital, LP |
13D/G
Matthew Smith
|
9.4%
|
$4,980,934
1,119,311 shares
|
+$829,645 | 30 Jun 2025 |
| Weinstein Benjamin |
13D/G
|
5.2%
|
$2,107,956
395,489 shares
|
$0 | 18 Mar 2025 |
| NOVARTIS PHARMA AG |
3/4/5
13D/G
10%+ Owner
|
3.7%
from 13D/G
|
$4,590,753
12,407,440 shares
|
— | 15 Jun 2022 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
3.7%
|
$2,165,312
406,250 shares
|
$0 | 31 Mar 2025 |
| Bleichroeder LP |
13F
Company
|
4.2%
|
$4,515,000
1,075,000 shares
|
— | 30 Jun 2025 |
| Lynx1 Capital Management LP |
13F
Company
|
4%
|
$4,351,414
1,036,051 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
54
Shares
4,649,562
Rows available
54
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
51
Q3 2025 holders
54
Holder diff
3
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend